首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1441233

全球肺炎治療市場規模、佔有率、成長分析（按治療方法和分銷管道）- 產業預測，2023-2030 年

Global Pneumonia Therapeutics Market Size, Share, Growth Analysis, By Treatment(Antibiotics, antiviral drugs), By Distribution channel(Hospital pharmacies, retail pharmacies) - Industry Forecast 2023-2030

出版日期: 2024年02月22日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球肺炎治療市場規模為95億美元，從2023年的103.6億美元成長到2031年的206.3億美元，預測期內（2024-2031年）複合年成長率為9.0%。

全球肺炎治療市場受到多種因素的推動，包括肺炎盛行率的增加，特別是在老年人和免疫力缺乏的個體中，以及創新治療方法的持續發展。在醫療機構之外發生的社區型肺炎 (CAP) 仍然是一個重大問題，這導致人們對早期診斷和適當治療的認知不斷提高。這種意識正在推動診斷技術的改進、更準確的評估工具的開發以及為醫療保健專業人員制定最佳化治療結果的指南。這個市場包括各種抗生素、抗病毒藥物和支持性護理。醫療技術的進步和對個人化醫療的日益重視正在將研究和開發工作轉向更有針對性和更有效的治療。然而，一些地區仍面臨抗生素抗藥性和獲得醫療服務有限等挑戰。總體而言，由於不斷的醫療進步和人口趨勢，肺炎治療市場有望成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

輝瑞公司-美國
葛蘭素史克 (GSK) -英國
阿斯特捷利康公司 -英國
瑞士諾華公司
瑞士羅氏控股公司
默克公司 -美國
法國賽諾菲
強生公司 -美國
禮來公司 -美國
德國拜耳公司
勃林格殷格翰-德國
艾伯維公司-美國
百時美施貴寶 -美國
梯瓦製藥工業股份有限公司-以色列
Mylan NV-美國
Allergan（艾伯維旗下）－美國
Vertex Pharmaceuticals-美國
Astellas Pharma Inc.-日本
第一三共株式會社-日本
武田藥品工業株式會社-日本

簡介目錄

Product Code: SQMIG35A2498

Global Pneumonia Therapeutics Market size was valued at USD 9.50 Billion in 2022 and is poised to grow from USD 10.36 Billion in 2023 to USD 20.63 Billion by 2031, at a CAGR of 9.0% during the forecast period (2024-2031).

The global pneumonia therapeutics market is propelled by various factors, including the increasing prevalence of pneumonia, particularly among the elderly and immunocompromised individuals, and the continuous development of innovative treatment options. Community-acquired pneumonia (CAP), acquired outside of healthcare facilities, remains a significant concern, leading to heightened awareness regarding early diagnosis and appropriate treatment. This awareness has spurred improvements in diagnostic techniques, more accurate assessment tools, and the establishment of guidelines for healthcare practitioners to optimize treatment outcomes. The market encompasses a variety of antibiotics, antiviral drugs, and supportive care therapies. With ongoing advancements in medical technology and a growing emphasis on personalized medicine, research and development efforts are directed towards more targeted and efficient treatments. However, challenges such as antibiotic resistance and limited healthcare access in certain regions persist. Overall, the pneumonia therapeutics market is positioned for growth due to ongoing medical advancements and demographic trends.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumonia Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Pneumonia Therapeutics Market Segmental Analysis

The global pneumonia therapeutics market can be segmented based on treatment, distribution channel, and region. Treatment types include antibiotics, antiviral drugs, and supportive care. Distribution channels involve hospital pharmacies, retail pharmacies, and online platforms. Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Drivers of the Global Pneumonia Therapeutics Market

Pneumonia represents a substantial global health concern, particularly affecting vulnerable populations such as the elderly, young children, and individuals with compromised immune systems. The increasing prevalence of pneumonia is a key driver for the demand for effective therapeutics to address the condition.

Continued research and development endeavors have resulted in the identification of new treatment options and innovative approaches for pneumonia. These advancements have the potential to enhance the efficacy of existing treatments or introduce novel therapies, contributing to the expansion of the market and offering improved treatment outcomes for patients.

Restraints in the Global Pneumonia Therapeutics Market

Antibiotic resistance poses a significant challenge in the treatment of pneumonia. The overuse and misuse of antibiotics have led to the emergence of drug-resistant bacterial strains, diminishing the effectiveness of certain treatments. This constrains the available options for pneumonia treatment and underscores the necessity for alternative therapies.

The development and production of new pneumonia therapeutics often involve substantial costs, which can be transferred to patients and healthcare systems. The elevated expenses associated with treatment may restrict access to effective therapies, particularly in regions with limited healthcare resources or a lack of insurance coverage.

Market Trends of the Global Pneumonia Therapeutics Market

There was a growing emphasis on research and development in the field of pneumonia therapeutics. In response to the emergence of drug-resistant bacterial strains and the imperative for more effective treatments, pharmaceutical companies were actively investing in the development of novel antibiotics and alternative therapeutic approaches to combat pneumonia. This trend gained significance due to concerns about the potential for antibiotic-resistant infections.

Pneumonia, being a preventable disease, witnessed a strong focus on vaccination efforts, particularly for high-risk populations such as the elderly, young children, and individuals with compromised immune systems. Vaccines like the pneumococcal conjugate vaccine (PCV) and the influenza vaccine were actively promoted to reduce the incidence of pneumonia and its associated complications.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Pneumonia Therapeutics Market by Treatment

Market Overview
Antibiotics
antiviral drugs
and supportive care

Global Pneumonia Therapeutics Market by Distribution channel

Market Overview
Hospital pharmacies
retail pharmacies
and online platforms

Global Pneumonia Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi - France
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. - Israel
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (now part of AbbVie) - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Co., Ltd. - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments